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Abstract: Ovarian small-cell carcinoma of the hypercalcemic type is a rare and highly
malignant tumor. In two thirds of the patients, the tumor is associated with asymptomatic
paraneoplastic hypercalcemia. The diagnosis may be impeded; the tumor must be
distinguished from other tumors with similar features.
This tumor occurs predominantly in young women and is merely lethal. The 1-year
survival is solely 50%, with an overall 5-year survival rate of approximately 10%. It is
believed that the empirical treatment characterized by combination of radical surgery,
chemotherapy, and radiotherapy results in the most favorable outcome in terms of survival.
However, the outcome remains extremely poor despite this aggressive approach.
Alternatively, these poor survival rates may justify a less aggressive fertility sparing
approach without compromising the outcome. Such an approach is illustrated by a case report
involving a patient with ovarian small-cell carcinoma of the hypercalcemic type, FIGO stage
IIIC. A fertility-sparing approach was used, consisting of conservative surgery followed by
induction chemotherapy, interval debulking surgery, and local radiotherapy. During follow-up
of 60 months, there was no evidence of disease and the normal menstrual cycle resumed.
In addition to this case report, histopathological features, different therapeutic modal-
ities, and outcome of ovarian small-cell carcinoma of the hypercalcemic type is reviewed.
This report suggests that a fertility-sparing approach may be just as feasible as the gen-
erally applied aggressive approach.
Key Words: Ovarian cancer, Small-cell carcinoma of the hypercalcemic type,
Conservative surgery, Neoadjuvant chemotherapy, Survival
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The rare ovarian small-cell carcinoma of the hypercalcemic typeis predominantly observed in young women. Fewer than 250
cases have been reported in the literature.1,2 Ovarian tumors in
young women are often germ-cell or sex-cord tumors, whereas
ovarian small-cell carcinomas of the hypercalcemic type represent
a minority. The average age of occurrence of these tumors is
23.9 years (range, 1Y55 years).3Y5
Ovarian small-cell carcinoma of the hypercalcemic type is
generally in FIGO stage III at first presentation.6 In most cases, a
unilateral tumor is present. The average diameter of the tumor is
15 cm (range, 6Y26 cm).3 The 1-year survival is solely 50%, with
an overall 5-year survival rate of approximately 10%.3,7
The scarcity, the histological features, the unsolved origin
of these tumor cells, and wide range of potential differential diag-
noses impede pathological characterization.3,8 An accurate diagno-
sis is mandatory in relation to the therapeutic consequences.9,10
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It is widely believed that a combination of treatment moda-
lities, consisting of radical surgery, chemotherapy, and radiotherapy,
results in the most favorable outcome in terms of survival. However,
this aggressive approach is empirically established based on single
case histories and small series.2,11 It is under debate whether the
poor survival rates of ovarian small-cell carcinoma of the hypercal-
cemic type justify aggressive treatment modalities without obtaining
a reasonable outcome. Alternatively, the dramatically poor survival
rates and subsequently, the limited time to have children, may com-
promise the need for less aggressive fertility sparing approaches.
A review of the available literature regarding the pathological
characterization, various treatment modalities, and outcome is
summarized. As a consequence of the poor outcome, especially in
the advanced stages of disease, a fertility sparing approach may be
just as justified as an aggressive radical approach. The feasibility of
such a fertility sparing approach is illustrated by a case report.
CASE REPORT
A 23-year-old woman presented an acute abdomen. A right-
sided ovarian tumor with a diameter of 13 cm was found. There was
no significant past medical history and the menstrual cycle was
normal. Laboratory tests demonstrated an elevated C-reactive pro-
tein of 120 kU/L and white blood counts of 6.7  109/L. Other tests
were normal. Torsion of the right ovary was suspected, and a lapa-
rotomy was performed. A torsion of an enlarged right ovary was
diagnosed with a normal aspect of the left ovary, uterus, and other
intra-abdominal organs. Retroperitoneal lymph nodes were regarded
as reactively enlarged. The right adnex was surgically resected.
Preliminary pathological assessment of the right ovary yielded the
diagnosis of ovarian dysgerminoma.
The patient was referred to a tertiary referral center for fur-
ther treatment. Vaginal ultrasound and x-ray showed no abnor-
malities. Computed tomography scan of the abdomen and pelvis
demonstrated enlarged retroperitoneal lymph nodes (renal and pa-
raaortal). Laboratory tests showed elevated ASAT, LDH, and Ca-125
serum levels (41 U/L, 488 U/L, and 45 kU/L, respectively). All
other tests, including serum calcium levels, human chorionic
gonadotropin (hCG), and >-fetoprotein (AFP) were normal. Oral
contraceptives were administered in an effort to preserve ovarian
function.12 Based on the initial diagnosis of dysgerminoma and
the enlarged paraaortic lymph nodes, treatment was initiated
with bleomycin, etoposide, and cisplatin (BEP) cycles (bleomycin
30 mg/m2 days 2, 8, 15; etoposide 100 mg/m2 days 1Y5; cisplatin
20 mg/m2 days 1Y5). Revision of the pathology yielded a diag-
nosis of ovarian small-cell carcinoma of hypercalcemic type.
The tumor was described macroscopically as 11  7  5 cm with
an incomplete capsule and areas of necrosis and bleeding. Mic-
roscopic examination of the tumor showed closely packed small
round cells arranged in nests with comparatively small nuclei and
scanty cytoplasm. There were striking follicle-like spaces filled
with eosinophilic material in some areas. Larger tumor cells with
eosinophilic cytoplasm and large paler nuclei with prominent nuc-
leoli were also present in some areas, and there were extensive areas
of necrosis (Fig. 1). The mitotic rate was high, mean of 5 per HPF
in the areas with small-cell morphology.
Immunohistochemistry showed widespread positive staining
for CAM 5.2, CD 10, and p53, whereas in some areas, staining with
pankeratin was present. There was also focal staining for epithelial
membrane antigen (EMA), and neuron-specific enolase (NSE)
FIGURE 1. Hematoxylin and eosin slides of small-cell
carcinoma of the hypercalcemic type of the right ovary in a
23-year woman. A population of small, hyperchromatic tumor
cells surrounds follicle-like spaces (200). Insert: a small-cell
pattern is visible with a hypocellular region surrounded by
polygonal cells (400).
TABLE 1. Immunohistochemical profile of the presented
patient with ovarian small-cell carcinoma to the
hypercalcemic type
Immunohistochemistry in Ovarian Small-Cell Tumor of the
Hypercalcemic Type
Extensive/
Moderate
Positive
Focal/
Occasional
Positive Negative
Immunohistochemical markers:
AFP X
Alk1 X
CAM 5.2 X
CD10 X
CD30 X
CD45 X
CD117 X
Chromoganin X
Cytokeratin X
Desmin X
EMA X
hCG X
Inhibin X
NSE X
Okt 3/4 X
p12 X
p53 X
Pankeratin X
PTHrP X
PLAP X
S100 X
Vimentin X
Markers are in alphabetical order and the BX[ represents that staining was
either extensive-moderate positive, focal-occasional positive, or negative.
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was demonstrated. Inhibin was very focally positive. WT1 showed
intense cytoplasmatic positivity. Staining was negative for chromo-
granin, S100, desmin, placental alkaline phosphatase (PLAP), c-kit
protein (CD117), CD30, hCG, AFP, CD45, OCT 5, and ALK1.
Over-expression of 12p by in situ hybridization13 was absent.
Based on the morphology and the immunohistochemical features
(Table 1), this high-grade malignant tumor was diagnosed as an
ovarian small-cell carcinoma of the hypercalcemic type.
After the final diagnosis of ovarian small-cell carcinoma of
the hypercalcemic type, computed tomography scan was repeated
and showed regression of the lymph nodes after the first 2 BEP
cycles. It was therefore decided to continue the treatment and
complete a total of 4 BEP cycles. After the fourth BEP cycle, there
was a partial remission. The patient underwent a debulking and
staging surgery. No macroscopic or microscopic tumor was found
intra-abdominally. The uterus and left ovary were normal with no
macroscopic sign of malignancy. Retroperitoneal enlarged lymph
nodes were palpated and resected.
The histology of the resected lymph nodes showed tumor
cells of the large cell type, arranged in nests, with eccentric nuclei
and sometimes with intracytoplasmatic hyaline globules. Peritoneal
biopsies were free of tumor cells. After the resection of the para-
aortic lymph nodes, the paraaortal region was irradiated with 46 Gy
in 23 fractions of 2 Gy. A full remission was established for at
least 68 months, and the normal menstrual cycle had resumed.
OVARIAN SMALL-CELL CARCINOMA OF THE
HYPERCALCEMIC TYPE
Clinical Presentation
Patients with small-cell carcinoma of hypercalcemic type
present with symptoms similar to other ovarian tumors such as
lower abdominal pain and/or pelvic pain, enlargement of the ab-
domen, weight loss, nausea, vomiting, and anorexia.2,3,5 Two thirds
of these cases are associated with hypercalcemia,3 although only
2.5% of these patients present symptoms of hypercalcemia.6 Our
patient had normal serum calcium levels. In general, the increased
serum calcium levels decline to physiological levels after com-
plete surgical resection of the tumor and increase with recurrence.
Serum calcium levels may serve as a marker for treatment re-
sponse and recurrences.14 The pathophysiology of hypercalcemia
is unclear. It has been postulated that parathyroid hormone or pa-
rathyroid hormone-related protein (PTHrp) or a tumor-induced
calcium release by nontumor-related tissues may play a vital role.1,8
Etiology
This tumor was described as a distinct entity for the first
time in 1982.2 It should be distinguished from small-cell carcino-
ma of the pulmonary type, neuroendocrine carcinoma and from
metastatic pulmonary small-cell carcinoma and can easily be con-
fused with the highly malignant germ cell tumors of the ovary,
specifically dysgerminoma and granulosa cell tumors.3,15Y17 The
origin of ovarian small-cell carcinoma of the hypercalcemic type
is unclear.2 A germ cell as origin for this type of ovarian tumor
has been suggested.6 However, electron microscopic examina-
tion has demonstrated the presence of epithelial features.18 A num-
ber of cases have been reported of a familial occurrence of this
tumor.6,12,19 The evidence for a germ cell origin and inheritance
remains inconclusive, the tumor may be a unique tumor entity.1,10
Histopathological Analysis
The pathological assessment of ovarian small-cell carcinoma
of the hypercalcemic type may be problematic by reason of simi-
larities with other ovarian neoplasms and the unsolved origin of
these tumor cells.3,8,16 Moreover, approximately 50% of these tu-
mors exhibit a large cell component besides the typically small
round cells with scant cytoplasm.20 The presence of solely large
cell tumor observed in the surgically removed lymph nodes after
neoadjuvant chemotherapy in our patient is noteworthy. In these
tumors, numerous mitoses are commonly present, varying from
field to field, ranging 16 to 50 per 10 high power fields.3 Assess-
ment of this tumor can be also be hindered by the lack of any
specific immunohistochemical profile.8,21
FIGURE 2. Proposed algorithm for the treatment of patients with small-cell carcinoma of the hypercalcemic type of the ovary.
The proposed alternatives of conservative surgery may have an equally grim prognosis. However, the consequence of these
alternative approaches may not affect future fertility and endocrine issues of these young patients.
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Staining for vimentin22 and cytokeratin23 is generally posi-
tive in ovarian small-cell carcinoma of the hypercalcemic type.8
However, these are not specific markers for this tumor.23Y25
Parathyroid hormone-related protein is frequently focally posi-
tive.3,26 In addition, EMA and NSE may be present.8,27,28 Although
other ovarian tumors may carry these 2 markers,28Y30 EMA has
been asserted to be rarely found in sex-cord tumors that can form
an important part of the differential diagnosis.8,31Y35 However, it
has been reported that juvenile granulosa cell tumors could stain
positively with EMA.36 The focal presence of inhibin37 in our
patient complicated pathological assessment given that granulosa
cell tumors usually stain with this marker.38 Since the time of
the diagnosis, there has been further study of these lesions, which
has shown positivity with CD 10 and WT1 (usually nuclear but in
some cases cytoplasmatic staining). Both of these markers were
positive in our tumor.31,35 In our case, the extremely high mitotic
rate and clinical presentation (stage 3 with lymph node metastases
at presentation) argue against this diagnosis, and the further im-
munohistochemical profile is supportive for a diagnosis of small-
cell carcinoma of hypercalcemic type.39 Negative staining with a
range of other immunohistochemical markers, coupled with the
morphology, excluded other important tumors such as germ cell
tumor (AFP, PLAP, CD30, hCG) and lymphoma (CD45, CD30,
ALK1) in our patient.8,21,31 The immunohistochemical character-
ization of ovarian small-cell carcinoma of the hypercalcemic type
is summarized in Table 1.
With flow and image cytometry, however, the neoplastic cells
may show a diploid DNA content. Accumulation of the p53 protein
has been shown by genetic analysis in 12 of 15 of these tumors,
supporting an important role for p53 gene abnormalities in the
genesis of this highly aggressive ovarian carcinoma.7 Positive stain-
ing for p53 of ovarian small-cell carcinoma of the hypercalce-
mic type has been reported previously.31 Alternatively, gain of 12p
sequences has been described in (ovarian) germ cell tumors.13 The
lack of over expression of 12p in our case and positive staining
for p53 supported the diagnosis of ovarian small-cell carcinoma
of the hypercalcemic type.
Prognostic Factors
Small-cell carcinoma of the hypercalcemic type is a very
aggressive tumor with a grim prognosis. Only patients with a stage
IA disease have a reasonable chance of long-term survival. Tumor
stage is considered to be the most powerful prognostic factor.
Thirty-three percent of the patients with a stage IA tumor
had a long-term recurrence-free survival in contrast to only 10%
of patients with stage IC disease and 6.5% of those in advanced
stages.3 In stage IA disease, the prognosis was better when
patients were older than 30 years, had a normal serum calcium,
the tumor was smaller than 10 cm, and when it had no or few large
cells. In addition, a tendency toward a better outcome was ob-
served in patients who were treated by a bilateral salpingo-
oophorectomy, a total abdominal hysterectomy, chemotherapy, and
adjuvant radiotherapy compared with those missing 1 or more of
these modalities.3,40
The number of mitotic figures has no influence on survival
and is similar in the various stages of disease.
THERAPEUTIC OPTIONS
Surgery
Although early stage ovarian small-cell carcinoma of the
hypercalcemic type is unilateral in 99% of patients,3 various re-
ports support radical surgery with extirpation of the uterus and
both ovaries.9 Although there is a trend toward better outcome, the
number of patients is very low and therefore the efficacy of this
approach in premenopausal women is controversial.
It may be deemed desirable to preserve fertility in these
young patients. Hence, conservative surgical treatment with spar-
ing the contralateral ovary and uterus might be considered in ear-
ly stage disease.41,42 However, in spite of the poor prognosis for
patients with advanced stage small-cell carcinoma of the hyper-
calcemic type, an aggressive approach with radical resection followed
by chemotherapy is widely applied.9,34 Conservative debulking
TABLE 2. Reported strategies of treatment in ovarian
small-cell carcinoma of the hypercalcemic type
Strategies Used for Ovarian Small-Cell Carcinoma of the
Hypercalcemic Type
Combinations of Agents and Chronology Reference
Recommended treatment strategy:
-surgery, followed by cisplatin and
etoposide or BEP and radiotherapy
Harrison et al40
-neoadjuvant BEP, followed by
conservative surgery and radiotherapy
This report
Alternative treatment strategies
including radiotherapy:
-surgery, followed by cisplatin
and vinblastine
Young et al3
-surgery, followed by cisplatin,
etoposide, adriamycin, and vincristine
Young et al3
-surgery followed by VPCBAE or
neoadjuvant VPCBAE followed by surgery
Senekjian et al45
Alternative treatment strategies
without radiotherapy:
Double agent chemotherapy
-surgery followed by etoposide
and adriamycin
Hamilton et al46
-surgery followed by paclitaxel
and carboplatin
Wynn et al47
Triple agent chemotherapy
-surgery followed by BEP Reed et al34
-surgery followed by PAC Pruett et al10
Sequential chemotherapy
-surgery followed by vincristine,
etoposide and cyclophosphamide
and subsequently alternating
cisplatin and doxorubicin
Florell et al48
Induction chemotherapy
-induction with VAC followed
by surgery and consolidation with VPB
Patsner et al9
-induction with BEP followed
by surgery and consolidation with VAC
Powell et al47
The recommended strategy consists of a combination of surgery, radio-
therapy and cisplatin/etoposide-based chemotherapy. Surgery is generally
characterized by total hysterectomy and bilateral salpingo-oophorectomy.
Strategy of neoadjuvant BEP followed by conservative surgery is proposed
by this report. The summarized alternative treatment strategies are either
more toxic or inferior in comparison to the recommended strategy.
Vinblastine, cisplatin, cyclophosphamide, bleomycin, adriamycin, and
etoposide (VPCBAE), cisplatin, adriamycin, and cyclophosphamide (PAC),
vinblastine, cisplatin, and bleomycin (VPB).
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surgery followed by chemotherapy and local radiotherapy, however,
can be a reasonable alternative approach as illustrated by this case
report. Because of the grim prognosis of this disease, regardless of any
therapeutic approach, an alternative approach of conservative surgery
followed by chemotherapy is proposed (Fig. 2).
Chemotherapy
Patients with ovarian small-cell carcinoma of the hypercal-
cemic type receiving adjuvant chemotherapy after surgical inter-
vention may have a better chance on survival, even in FIGO stage
IA, compared with those not treated with adjuvant combination
chemotherapy.43,44
A large variety of chemotherapy regimens, all with limited
success, have been applied in the treatment of advanced and re-
current disease (Table 2). Chemotherapy regimes based on the
treatment of epithelial carcinoma, CP, CAP, and CHAP (cyclophos-
phamide, cisplatinum with or without doxorubicine and hexam-
ethylmelamine), had no or only little efficacy, and only responses
of short duration were observed.6,10,12,44,49,50 The same limited effect
has been observed with paclitaxel platinum therapy in advanced stage
disease,47 2 patients progressed during chemotherapy and 2 patients
shortly after the last chemotherapy cycle.40 The most favorable results
were achieved with BVP and BEP (cisplatinum, bleomycin with
vinblastin, or etoposide) regimen used in germ cell tumors.40
Poor survival rates may justify a tendency toward more com-
plex approaches consisting of 5 or more different chemotherapeu-
tic agents. Long-term survivors in stage III disease were observed
in patients treated with a multiagent chemotherapy consisting of
regimen alternating cycles with vinblastine, cisplatin, bleomycin
(PVB) and cyclophosphamide, doxorubicin, and etoposide with
and without ifosfamide.3,11 Another limited number long-term survi-
vors in stage III disease were treated with a regimen consisting of
postoperative induction therapy with BEP followed by consolida-
tion courses of vincristine, actinomycin-D, and cyclophosphamide
(VAC)51 or a regimen consisting of 5 to 6 chemotherapeutic agents
(combinations of vinblastine, cisplatin, cyclophosphamide, bleomy-
cin, adriamycin, doxorubucin, and etoposide).45,48 However, effi-
cacy and efficiency of these regimens in comparison with the BEP
regimen remains to be established.
Radiotherapy
In the literature, most of the patients with a long-term
survival had received radiotherapy after or concurrent with chemo-
therapy.2,3,40 Radiotherapy was administered as whole abdomi-
nal or pelvic and paraaortic radiotherapy. In the study of Harrison
et al,40 5 of the 7 patients who received radiotherapy after or
concurrent with chemotherapy are long-term survivors. Three of
the 4 patients with stage I disease who did not receive radiothe-
rapy had recurrent disease. In addition, the Young et al3 study
showed that 4 of the 5 patients receiving radiotherapy were long-
term survivors. Our patient with FIGO stage IIIC disease with
enlarged paraaortic lymph nodes was treated local radiotherapy
to the paraaortic region. Because of the obvious low number of
patients, the possible additional benefits of radiotherapy, in terms
of survival, remain to be established.
CONCLUSIONS
Ovarian small-cell carcinoma of the hypercalcemic type is a
rare diagnosis with a grim prognosis, which predominantly occurs
at a young age. The tumor can easily be confused with the highly
malignant germ cell tumors of the ovary, or with granulosa cell
tumors, and should be distinguished from small-cell carcinoma of
the pulmonary type, neuroendocrine carcinoma, and from metasta-
ses of the pulmonary small-cell tumor.
Although various option of treatment have been described,
the best treatment results in early stage disease have been achieved
with a multimodality approach consisting of surgery, combination
chemotherapy including cisplatinum and etoposide, and radiother-
apy (Table 2). This approach resembles largely to the approach of
the presented case in stage III disease, resulting in a good outcome
and fertility preservation. The treatment regimen was characterized
by conservative surgery, 4 cycles BEP (neoadjuvant) chemotherapy,
interval debulking surgery, and local radiotherapy to the paraaortic
region.
As suggested, the fertility sparing multimodality approach
might be feasible for both advanced and early stage disease in ovar-
ian small-cell carcinoma of the hypercalcemic type. A noninferior-
ity trail, comparing a fertility sparing approach with the widely
practiced aggressive approach, may show the efficacy of a fertil-
ity sparing approach. However, because of the low incidence of this
disease, a global rare tumor registration may be a realistic alternative
to determine the most favorable treatment option in advanced stage
ovarian small-cell carcinoma of the hypercalcemic type.
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